{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:40:15Z","timestamp":1777394415491,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2017,2,20]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    There is uncertainty about the efficacy and tolerability of zonisamide for Parkinson\u2019s disease (PD).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective:<\/jats:bold>\n                    We performed a meta-analysis of zonisamide treatment in PD patients who received antiparkinson drugs such as levodopa.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The primary outcome measures were the Unified Parkinson\u2019s Disease Rating Scale (UPDRS) Part III scores, wearing-off time, and discontinuation rate due to all causes. Secondary outcome measures were UPDRS total and subscale scores; discontinuation rates due to adverse events, inefficacy, and death; and individual adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Four randomized placebo-controlled trials including 1,068 PD patients were analyzed. All studies were conducted in Japan. UPDRS Part III scores were significantly lower with zonisamide than with placebo (weighted mean difference [WMD], \u20132.56; 95% confidence interval [CI]; \u20134.20 to \u20130.92;\n                    <jats:italic>p<\/jats:italic>\n                    \u200a=\u200a0.002). Further, zonisamide significantly decreased the wearing-off time compared with placebo (standardized mean difference, \u20130.24; 95% CI, \u20130.39 to \u20130.09;\n                    <jats:italic>p<\/jats:italic>\n                    \u200a=\u200a0.001). Discontinuation rates due to all causes were similar between the zonisamide and placebo groups (risk ratio, 1.29; 95% CI, 0.90 to 1.84;\n                    <jats:italic>p<\/jats:italic>\n                    \u200a=\u200a0.16). While zonisamide also decreased both UPDRS Part II (off-time) and UPDRS total scores compared to placebo (UPDRS Part II [off-time] scores: WMD, \u20130.79; UPDRS total scores: WMD, \u20132.51), there were no significant differences in other secondary outcomes between the two groups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Our results suggested that zonisamide combination therapy was beneficial in treating motor symptoms in PD patients receiving antiparkinson drugs and was well tolerated in Japanese patients. Future studies in populations other than the Japanese are needed.\n                  <\/jats:p>","DOI":"10.3233\/jad-161068","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T09:31:07Z","timestamp":1486114267000},"page":"1229-1239","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":26,"title":["Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson\u2019s Disease: A Meta-Analysis"],"prefix":"10.1177","volume":"56","author":[{"given":"Shinji","family":"Matsunaga","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,2]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/ldn013"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70471-9"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg068"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25945"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810083391506"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.09.021"},{"key":"e_1_3_3_10_2","unstructured":"National Institute for Health and Care Excellence (2006) Parkinson\u2019s disease in over 20s: Diagnosis and management https:\/\/www.nice.org.uk\/guidance\/cg35\/chapter\/1_639-guidance."},{"key":"e_1_3_3_11_2","first-page":"590","article-title":"Part 2: Introduction to the pharmacotherapy of Parkinson\u2019s disease, with a focus on the use of dopaminergic agents","volume":"40","author":"DeMaagd G","year":"2015","unstructured":"DeMaagdG, PhilipA (2015) Part 2: Introduction to the pharmacotherapy of Parkinson\u2019s disease, with a focus on the use of dopaminergic agents. P T 40, 590\u2013600.","journal-title":"P T"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2012.03866.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23517"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(01)00298-X"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00188a011"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(92)90087-A"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(03)00183-9"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701941"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0920-1211(95)00078-X"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2010.04.017"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756285609338501"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000250236.75053.16"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26286"},{"issue":"2016","key":"e_1_3_3_24_2","first-page":"10","article-title":"Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease","volume":"4","author":"Murata M","year":"2015","unstructured":"MurataM, HasegawaK, KanazawaI, ShirakuraK, KochiK, ShimazuR, The Zonisamide PD, Study, Group (2015) Randomized placebo-controlled trial of zonisamide in patients with Parkinson\u2019s disease. Neurol Clin Neurosci 4(2016), 10\u201315.","journal-title":"Neurol Clin Neurosci"},{"issue":"9","key":"e_1_3_3_25_2","first-page":"S198","article-title":"Randomized, double-blind study of zonisamide with placebo in advanced Parkinson\u2019s disease","volume":"19","author":"Murata M","year":"2004","unstructured":"MurataM, HasegawaK, KanazawaI (2004) Randomized, double-blind study of zonisamide with placebo in advanced Parkinson\u2019s disease. Mov Disord 19(Suppl 9), S198.","journal-title":"Mov Disord"},{"key":"e_1_3_3_26_2","first-page":"153","volume-title":"Recent developments in Parkinson\u2019s disease","author":"Fahn S","year":"1987","unstructured":"FahnS, EltonR, Members of the UPDRS, Development, Committee (1987) Unified Parkinson\u2019s disease rating scale. In: FahnS, MarsdenCD, CalneD, GoldsteinM, eds. Recent developments in Parkinson\u2019s disease. Vol 2. Florham Park, NY: Macmillan Healthcare Information, 153\u2013163, 293\u2013304."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.8.3.243"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.11.009"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2010.46.4.1490077"},{"key":"e_1_3_3_33_2","unstructured":"HigginsJPT GreenS (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In The Cochrane Collaboration http:\/\/handbook.cochrane.org."}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-161068","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-161068","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-161068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:03:10Z","timestamp":1777370590000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-161068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,2,20]]}},"alternative-id":["10.3233\/JAD-161068"],"URL":"https:\/\/doi.org\/10.3233\/jad-161068","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}